Compare VanEck Gold Miners ETF (GDX) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Regeneron Pharmaceuticals Inc — how do they compare? VanEck Gold Miners ETF trades at $88.4 (market cap $25.65B), while Regeneron Pharmaceuticals Inc trades at $745.9 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3× VanEck Gold Miners ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| GDX | REGN | |
|---|---|---|
Market Cap | $25.65B | $76.14B |
Volume | 16,534,046 | 500,239 |
52-Week High | $115.84 | $852.03 |
52-Week Low | $68.28 | $557.73 |
Typical Hold Time | 76 Days | 107 Days |
Sector | — | Health |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX, the VanEck Gold Miners ETF, trades at $85.46, down 3.13% amid a bearish technical signal with 13 sell signals from moving averages. Recent news highlights pressure on gold miners from rising interest rates and silver's sharp decline, though some analysts see value in the sell-off. Key support lies at $84, with resistance at $86-87. The ETF offers exposure to gold mining equities but lacks disclosed fundamental ratios in this snapshot.
The outlook for GDX hinges on gold price direction and interest rate trends, with risks including metal volatility and macroeconomic headwinds. Opportunities exist if gold rebounds, but investor caution is warranted given technical weakness and mixed sentiment from institutional flows.
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
